Cintredekin besudotox, Recombinant human IL13
Cat# : THP-0191
| Cat#: |
THP-0191 |
| Product Name: |
Cintredekin besudotox, Recombinant human IL13 |
| Description: |
The product is made from a human protein, Interleukin 13 (IL13), linked to a bacterial toxin, Pseudomonas exotoxin (PE). The IL13 portion binds to receptors on the tumor. |
| Sequences: |
Not Available |
| Species: |
Human |
| Molecular Weight: |
Not Available |
| Purity: |
>99% by SDS-Page and HPLC analysis |
| Cas No: |
Not Available |
| Formula: |
Not Available |
| Endotoxin Level: |
<0.001 EU per 1 μg of the peptide by the LAL method |
| Drug Name: |
Cintredekin besudotox |
| Applications: |
Investigated for use/treatment in brain cancer. |
| Examples of Clinical Use: |
Brain cancer |
| Pharmacodynamics: |
Not Available |
| Mechanism of action: |
A recombinant chimeric protein with potent antitumor activity. Cintredekin besudotox is composed of interleukin-13 (IL13), a pleiotropic immunoregulatory cytokine, linked to a mutated form of pseudomonas exotoxin A; this agent targets and kills tumor cells that express the IL13 receptor (IL13R). The IL13 moiety attaches to the IL13R on the tumor cell membrane, facilitating the entry of the exotoxin. The exotoxin moiety induces caspase-mediated apoptosis of tumor cells via a mechanism involving mitochondrial damage; it also catalyzes the transfer of ADP ribose from nicotinamide adenine dinucleotide (NAD) to elongation factor-2 in eukaryotic cells, thereby inactivating elongation factor 2 and inhibiting protein synthesis. |
| Affected organisms: |
Humans and other mammals |
| Targets: |
Target 1. Interleukin-13 |
For research use only. Not intended for any clinical use. No products from Creative BioMart may be resold, modified for resale or used to manufacture commercial products
without prior written approval from Creative BioMart.
